Evidence map›Paper›PMID 41970527›Full record

ArticleAlzheimer's & dementia (New York, N. Y.)

A potential multimodal biomarker - cognitive signature associated with the conversion from subjective cognitive decline to mild cognitive impairment.

Mohamed Haddad, Mohamed Raâfet Ben Khedher, Chadi Ouechtati, Tamás Fülöp, Consortium for the early identification of Alzheimer's disease‐Quebec (CIMA‐Q), Charles Ramassamy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia (New York, N. Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mohamed HaddadCentre Armand-Frappier Santé Biotechnologie Institut National de la Recherche Scientifique Laval QC Canada.
Mohamed Raâfet Ben KhedherCentre Armand-Frappier Santé Biotechnologie Institut National de la Recherche Scientifique Laval QC Canada.
Chadi OuechtatiCentre Armand-Frappier Santé Biotechnologie Institut National de la Recherche Scientifique Laval QC Canada.
Tamás FülöpDepartment of Medicine, Geriatric Division, Research Center on Aging Sherbrooke University Sherbrooke QC Canada.
Consortium for the early identification of Alzheimer's disease‐Quebec (CIMA‐Q)
Charles RamassamyCentre Armand-Frappier Santé Biotechnologie Institut National de la Recherche Scientifique Laval QC Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe disruption of key mechanisms involved in amyloid beta (Aβ) clearance during the early stages of dementia may contribute to the progression of cognitive decline toward irreversible brain damage. In this study, we investigated multiple immune-related pathways implicated in the management and clearance of Aβ within circulating extracellular vesicles (cEVs) and serum from individuals with subjective cognitive decline (SCD) who later progressed to mild cognitive impairment (MCI).

methodsA cytokine panel and the levels of Aβ

resultsIn SCD patients, the concentrations of Aβ DISCUSSION: Our findings support the potential value of integrating serum M-CSF levels with RAVLT performance and cEVs Aβ

Indexed as

amyloid betacognitive performanceextracellular vesiclesneuroinflammationsubjective cognitive decline

Identifiers

PMID41970527
PMCPMC13069491

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.